FDA Expands Marstacimab Indication in Hemophilia A and B - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Expands Marstacimab Indication in Hemophilia A and B

Phase 3 BASIS and BASIS KIDS data supported the expanded indication across pediatric and inhibitor-pretreated populations.

  • By

  • Kathryn Wighton

  • June 8, 2026

  • 3 min

Share

Original Source(s)

FDA Expands Marstacimab Indication in Hemophilia A and B

  • by Kathryn Wighton

  • June 8, 2026

Related Content

Boosting Children’s Physical Activity in Outside School Hours Care

Serum Growth Differentiation Factor 15 Levels in School-Aged Children Born Preterm

Parental perspectives on gluten immunogenic peptide urine testing in children with coeliac disease: a qualitative study on barriers, emotions and interest in point-of-care tools